$ATTO 4 SEC Filings

Filed On	Filing
13 Aug 2026	Form 4: Walsh Colin, Director Bought 85,000 shares ($1.79M) · Sold 105,807 shares ($2.25M) · Received 2,435,632 shares by conversion · 1 more
13 Aug 2026	Form 4: Goldman Sachs Group Inc, Former 10% Owner and 7 others Bought 85,000 shares ($1.79M) · Sold 105,807 shares ($2.25M) · Received 2,435,632 shares by conversion · 1 more
10 Aug 2026	Form 4: Deep Track Biotechnology Master Fund, Ltd., 10% owner and 2 others Received 1,957,138 shares by conversion
10 Aug 2026	Form 4: venBio Global Strategic Fund IV, L.p., 10% owner Received 3,799,015 shares by conversion · Bought 382,352 shares ($6.5M)
07 Aug 2026	Form 4: Redmile Group, Llc, 10% owner and 2 others Received 782,854 shares by conversion · Bought 600,000 shares ($10.2M)
07 Aug 2026	Form 4: Sanofi, 10% owner Received 782,855 shares by conversion · Bought 300,000 shares ($5.1M)
06 Aug 2026	Form 4: Frazier Life Sciences XI, L.p., 10% owner and 2 others Received 5,490,629 shares by conversion · Bought 588,235 shares ($10M)
06 Aug 2026	Form 4: You Angie, Director Granted 27,000 Stock Option (Right to Buy)
06 Aug 2026	Form 4: Gold Mitchell, Director Granted 27,000 Stock Option (Right to Buy)
06 Aug 2026	Form 4: Odrowaz Zaneta, Chief Business Officer Granted 140,000 Stock Option (Right to Buy)
06 Aug 2026	Form 4: Veiby Petter, Chief Scientific Officer Granted 140,000 Stock Option (Right to Buy)
06 Aug 2026	Form 4: Chen Hubert, Chief Medical Officer Granted 140,000 Stock Option (Right to Buy)
06 Aug 2026	Form 4: Attovia Therapeutics, Inc., Chief Financial Officer Granted 140,000 Stock Option (Right to Buy)
06 Aug 2026	Form 4: Attovia Therapeutics, Inc., Director Granted 538,300 Stock Option (Right to Buy)

Comments